SCHEMBL5069743

SCHEMBL5069743

Cc1ccc(F)cc1-c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 3/20 0.43
▸ PDE10A Q9Y233 3/20 0.43
▸ AGPAT2 O15120 1/20 0.41
▸ NISCH Q9Y2I1 1/20 0.41
▸ ABL1 P00519 2/20 0.39
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HSD11B1 P28845 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ AMY1A P0DUB6 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ PLA2G7 Q13093 1/20 0.34
▸ CLCN2 P51788 1/20 0.34
▸ SLC9A1 P19634 1/20 0.34
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14364369 0.86 AQP1 (0.42) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL10094685 0.80 ABL1 (0.46) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL18772851 0.79 AGPAT2 (0.50) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL5069737 0.79 NISCH (0.36) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL9139591 0.78 NISCH (0.52) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL30377758 0.78 NISCH (0.52) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL22232224 0.77 ABL1 (0.43) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL8054650 0.76 ABL1 (0.49) PDE2APDE10AAGPAT2NISCHABL1
SCHEMBL12365161 0.76 ABL1 (0.49) AGPAT2ABL1PTGS2
SCHEMBL254861 0.73 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365196-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK SHARP & DOHME LTD. (GB) 2008-04-29 — — US disclosed
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK CANADA INC. (CA) 2004-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives BACE1, BACE2, PSEN2 PDE2A 4581/4885PDE10A 4509/4885AGPAT2 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback